Inmune Bio, Inc. (INMB): Form 8-K filed 2026-10-29

Items reported

Item 1.01: Entry into a Material Definitive Agreement
The company signed a material agreement outside the ordinary course of business, or materially amended one. Typical examples are credit agreements, merger agreements, large supply or licensing contracts and financing arrangements.
Item 3.02: Unregistered Sales of Equity Securities
The company sold equity securities in a transaction not registered under the Securities Act, such as a private placement, above a size threshold.
Item 7.01: Regulation FD Disclosure
The company is making information public under Regulation FD, which requires broad public disclosure of material information shared with certain market participants. Investor presentations and press releases are common. Like Item 2.02, this information is generally "furnished" rather than "filed".
Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.

Type	Description	Document
8-K	CURRENT REPORT	ea0309967-8k_inmune.htm
EX-4.1	FORM OF COMMON WARRANT	ea030996701ex4-1.htm
EX-5.1	OPINION OF SICHENZIA ROSS FERENCE CARMEL LLP	ea030996701ex5-1.htm
EX-10.1	FORM OF SECURITIES PURCHASE AGREEMENT, DATED OCTOBER 27, 2026, BY AND BETWEEN TH	ea030996701ex10-1.htm
EX-10.2	PLACEMENT AGENCY AGREEMENT, DATED OCTOBER 27, 2026, BY AND BETWEEN THE COMPANY A	ea030996701ex10-2.htm
EX-99.1	PRESS RELEASE DATED OCTOBER 28, 2026	ea030996701ex99-1.htm

This page lists what the filing reports; it does not summarize or interpret it. Read the original documents on SEC EDGAR. How to read an 8-K.